Wells Fargo & Company Rain Therapeutics Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.84 - $1.22 $1,026 - $1,490	1,222 Added 30.38%	5,245 $6,000
Q3 2023 Nov 13, 2023	SELL	$0.82 - $1.42 $2,137 - $3,701	-2,607 Reduced 39.32%	4,023 $3,000
Q2 2023 Aug 15, 2023	BUY	$1.09 - $9.93 $7,105 - $64,733	6,519 Added 5872.97%	6,630 $7,000
Q1 2023 May 12, 2023	BUY	$7.77 - $12.47 $326 - $523	42 Added 60.87%	111 $0
Q4 2022 Feb 13, 2023	BUY	$5.52 - $8.48 $5 - $8	1 Added 1.47%	69 $0

Q3 2022 Nov 14, 2022	SELL	$4.75 - $8.01 $4,664 - $7,865	-982 Reduced 93.52%	68 $0
Q2 2022 Aug 12, 2022	SELL	$2.21 - $5.56 $1,412 - $3,552	-639 Reduced 37.83%	1,050 $6,000
Q1 2022 May 16, 2022	SELL	$5.07 - $13.68 $29,994 - $80,930	-5,916 Reduced 77.79%	1,689 $9,000
Q4 2021 Feb 14, 2022	BUY	$11.91 - $17.0 $90,575 - $129,285	7,605 New	7,605 $98,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.